Abstract
Therapeutic management of cancer has undergone tremendous conceptual advance over the last couple of decades. Not only are we better acquainted with the intricate mechanisms leading to oncogenic transformation, but also the strategies to intercept and disturb these command and control pathways are becoming more specific and target-selective. One critical change is the realization that despite the existence of diverse mechanisms for the development of different sub-sets of cancers, there may indeed be central regulatory networks that serve as a common denominator in all forms of neoplasia. These critical events could endow cells with the potential for unabated proliferation, insensitivity to death inducing signals, and enhanced metastatic potential. Thus, developing strategies to target these critical events or pathways should significantly improve the outcome of cancer chemotherapy. The purpose of this review is to briefly discuss the complexities of the disease, highlight the current therapeutic strategies, and more importantly provide a mechanistic approach for future drug design aimed at targeting the traits of the disease and for favorably tailoring the response of cancer cells to drug therapy.
Keywords: anti-cancer drugs, curing cancer, therapeutic management, neoplasia, drug therapy, mechanistic approach to the design, antibiotics, novel strategies, fptase activity, remortalize the immortal
Current Pharmaceutical Design
Title: Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Volume: 8 Issue: 19
Author(s): Shazib Pervaiz
Affiliation:
Keywords: anti-cancer drugs, curing cancer, therapeutic management, neoplasia, drug therapy, mechanistic approach to the design, antibiotics, novel strategies, fptase activity, remortalize the immortal
Abstract: Therapeutic management of cancer has undergone tremendous conceptual advance over the last couple of decades. Not only are we better acquainted with the intricate mechanisms leading to oncogenic transformation, but also the strategies to intercept and disturb these command and control pathways are becoming more specific and target-selective. One critical change is the realization that despite the existence of diverse mechanisms for the development of different sub-sets of cancers, there may indeed be central regulatory networks that serve as a common denominator in all forms of neoplasia. These critical events could endow cells with the potential for unabated proliferation, insensitivity to death inducing signals, and enhanced metastatic potential. Thus, developing strategies to target these critical events or pathways should significantly improve the outcome of cancer chemotherapy. The purpose of this review is to briefly discuss the complexities of the disease, highlight the current therapeutic strategies, and more importantly provide a mechanistic approach for future drug design aimed at targeting the traits of the disease and for favorably tailoring the response of cancer cells to drug therapy.
Export Options
About this article
Cite this article as:
Pervaiz Shazib, Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?, Current Pharmaceutical Design 2002; 8 (19) . https://dx.doi.org/10.2174/1381612023394025
DOI https://dx.doi.org/10.2174/1381612023394025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Potential New Targets for Antithrombotic Therapy
Current Pharmaceutical Design Tissue Doppler Imaging: Beautiful Noise
Current Cardiology Reviews Critical Overview of Applications of Genetic Testing in Sport Talent Identification
Recent Patents on DNA & Gene Sequences Fetal Origins of Cardiovascular Disease
Current Cardiology Reviews S100A1: Structure, Function, and Therapeutic Potential
Current Chemical Biology Inhibition of Matrix Metalloproteinases (MMPs) as a Potential Strategy to Ameliorate Hypertension-Induced Cardiovascular Alterations
Current Drug Targets Inflammatory Markers in Coronary Artery Disease: Pathophysiological Mechanisms, Prognostic and Therapeutic Implications
Current Cardiology Reviews Editorial: (New Drug (LCZ696) for the Treatment of Heart Failure with Reduced Ejection Fraction After 10 Years. Can One Study Change the Guidelines?)
Current Vascular Pharmacology Altered Calmodulin Degradation and Signaling in Non-Neuronal Cells from Alzheimer’s Disease Patients
Current Alzheimer Research FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Supertargeted Chemistry: Identifying Relationships Between Molecular Structures and their Sub-Cellular Distribution
Current Topics in Medicinal Chemistry Meet Our Associate Editor
Current Cardiology Reviews Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index to Volume 2
Current Vascular Pharmacology